Antares Pharma (AIS)
Antares Pharma Beneish M-Score: -1.942
View AIS Beneish M-Score with YCharts Pro.
Access these YCharts Pro features:
Export any data you want
Save any chart as an image
Utilize advanced screener power
View 30 years of financial history
over 90 advanced calculations
Enjoy an advertising free experience
AIS Beneish M-Score Rankings
| Overall | 13th percentile | 3238 of 3761 |
| Sector | 18th percentile | 279 of 342 in Healthcare |
| Industry | 11th percentile | 55 of 62 in Medical Instruments & Supplies |
AIS Beneish M-Score Range, Past 5 Years
| Minimum | -3.438 | Dec 2009 |
| Maximum | -0.288 | Dec 2008 |
| Average | -2.222 |
About Beneish M Score
The Beneish M Score helps to uncover companies who are likely to be manipulating their reported earnings. Companies with a higher score are more likely to be manipulators. This is a probabilistic model, so it will not detect manipulators with 100% accuracy.
The best cut-off point depends on the costs mistakenly classifying in one of two ways:
1) Classifying firm that is manipulating earnings as a non-manipulator (Type I error), and
2) Classifying a firm as a manipulator when it actually was not manipulating (Type II Error).
Here are optimal cut-offs according to Beneish, presented as the score followed by the cost of Type I error relative to cost of Type II error):
M Score HTML Table:
| Score | Relative Error Costs (Type I:Type II) |
|---|---|
| M Score > -1.49 | (10:1) | M Score > -1.78 | (20:1) | M Score > -1.89 | (40+:1) |
Beneish excluded financial institutions from his sample when calculating the M-Score, so extreme care should be taken when looking at M-Scores of financial firms - their business models are different from the manufacturing and other service firms that Beneish used in his study.
If you want more details, here is the original Beneish M Score Paper, or you can learn about our calculation by clicking "Learn More" below.
Learn More
You may also be interested in these AIS related companies
AIS News
@ANDISIK try to get timing/Entry better next time $AIS.Over history its proven 2 bounce back,so buy big dips not tops,n you'll luv this name
about 2 hours ago by HighGrowthFinancial
about 2 hours ago by HighGrowthFinancial
@HighGrowthFinancial $AIS is not hard but impossible to predict the price movement. Kills me that I could be making $ elsewhere.
about 3 days ago by ANDISIK
about 3 days ago by ANDISIK
$AIS not buying this dip just yet, its been bouncing back from sub $3 everytime, not sure about this one though
about 3 days ago by HighGrowthFinancial
about 3 days ago by HighGrowthFinancial
@GPrime, $AIS, Example of making money elsewhere, bought SPPI yesterday at $10.76, its now at $11.20, a 4% gain.
about 3 days ago by ANDISIK
about 3 days ago by ANDISIK
$AIS, really does test your patience. If it can't hold ~ $2.90, I'm going to start getting out. Buy back when lower or go make $ elsewhere.
about 3 days ago by ANDISIK
about 3 days ago by ANDISIK
RT @casualtrader: Long $AIS Long will run into next earning date $CLSN Celsion buy @ 1,6 ~ 1,8 run up come by end of this year 8$ come
about 4 days ago by BioInvestor
about 4 days ago by BioInvestor
@casualtrader, $AIS. You should check out $SPPI, great company. I actually got back in today. ·
about 4 days ago by ANDISIK
about 4 days ago by ANDISIK
@markf @ANDISIK any other biotech ideas? Long $AIS, looking to initiate long position $ZLCS. Thoughts?
about 4 days ago by casualtrader
about 4 days ago by casualtrader
@markf $AIS not that I'm aware of.Just a safer long term biotech investment with huge potential. Don't need to put all $ in riskier biotechs
about 4 days ago by ANDISIK
about 4 days ago by ANDISIK
On 5/19/12 Columbine Capital Services upgraded $AIS from Neutral to Favorable.
about 6 days ago by ANDISIK
about 6 days ago by ANDISIK
RT @markf: $AIS on Aug 8th..?? on earnings day for $AIS next earning is Aug 7 or 8 2012 positive earning come 100%
about 10 days ago by BioInvestor
about 10 days ago by BioInvestor
Antares Pharma Appoints LeRoux Jooste Senior Vice President Pharmaceutical Sales and Marketing
May 15, 7:00AM Business Wire
May 15, 7:00AM Business Wire
Antares Pharma to Present at the 15th Annual Bank of America Merrill Lynch Health Care Conference
May 10, 7:00AM Business Wire
May 10, 7:00AM Business Wire
Antares Pharma Reports First Quarter 2012 Financial and Operating Results
May 08, 7:00AM Business Wire
May 08, 7:00AM Business Wire
Antares Pharma Announces Epinephrine Auto-Injector Settlement Agreement Between Teva and Pfizer
Apr 26, 9:26AM Business Wire
Apr 26, 9:26AM Business Wire
Watson and Antares Announce the Introduction of Gelnique 3%™, for the Treatment of Overactive Bladder
Apr 26, 7:00AM PR Newswire
Apr 26, 7:00AM PR Newswire
Antares Pharma to Present at the 11th Annual Needham Healthcare Conference
Mar 28, 7:00AM Business Wire
Mar 28, 7:00AM Business Wire
Antares Pharma and Boston Scientific Look to Make Headway in Surging Medical Supplies Industry
Mar 22, 8:20AM Marketwire
Mar 22, 8:20AM Marketwire
Antares Pharma Reports Fourth Quarter and Full Year 2011 Financial and Operating Results
Mar 12, 7:00AM Business Wire
Mar 12, 7:00AM Business Wire
Antares Pharma Appoints John J. Howarth Vice President of Corporate Affairs
Feb 27, 9:30AM Business Wire
Feb 27, 9:30AM Business Wire
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| AIS | 2.89 | +0.02 | +0.70% | 299.69M |
| AIRT | 9.250 | +0.17 | +1.87% | 22.66M |
| AIRM | 91.97 | -0.12 | -0.13% | 1.159B |
| AIR | 12.48 | -0.29 | -2.27% | 502.69M |
| AIQ | 1.05 | -0.02 | -1.87% | 55.99M |
| AMS | 3.09 | +0.03 | +0.98% | 14.24M |
| AMRS | 2.57 | +0.20 | +8.44% | 144.59M |
| AMRI | 2.71 | -0.05 | -1.81% | 83.39M |
| AMRC | 11.07 | -0.15 | -1.34% | 289.15M |
| AMPL | 0.185 | +0.01 | +2.83% | 10.38M |